Skip to main content
. 2015 Jun 20;12:20. doi: 10.1186/s12954-015-0054-1

Table 1.

Demographic characteristics, N = 30

Participants, N (%)
Age (years)a 52 (46–59)
Race
  Hispanic 22 (73)
  African American 4 (13)
  Others 4 (13)
HIV-HCV co-infection 7 (23)
HCV treatmentb 22 (73)

aGiven as median (IQR)

bTreatment administered as pegylated IFN and ribavirin; eight separate participants received pegylated IFN, telaprevir, and ribavirin